GLAUKOS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 99.48 USD | -0.63% |
|
+3.09% | +25.15% |
| Apr. 11 | Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating | MT |
| Apr. 11 | Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing | MT |
Presentation Operator MessageOperator (Operator)Welcome to Glaukos Corporation's Fourth Quarte...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
99.48
USD
Average target price
106.6
USD
Spread / Average Target
+7.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.15% | 4.99B | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B | |
| -22.81% | 1.79B |
- Stock Market
- Equities
- GKOS Stock
- News Glaukos Corporation
- Transcript : Glaukos Corporation, Q4 2021 Earnings Call, Feb 22, 2022
